Skip to main content

Table 3 Factors associated with change in E/e′ from baseline to 24 months

From: Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

 

Model 1

Model 2

Model 3

N = 115, R = 0.26

N = 115, R = 0.27

N = 115, R = 0.55

β

p value

β

p value

β

p value

Sitagliptin

−8.910

0.006

−8.887

0.007

−9.959

0.001

E/e′

−0.094

0.889

−0.159

0.820

−0.240

0.716

Male gender

  

0.674

0.845

0.149

0.966

Age

  

0.330

0.392

−0.005

0.990

Systolic blood pressure

    

−0.293

0.095

HbA1c

    

6.614

0.272

Cardiovascular disease

    

−5.631

0.142

Chronic heart failure

    

10.819

0.070

α-glucosidase inhibitor

    

1.053

0.734

Biguanide

    

−14.839

0.001

Glinide

    

−10.778

0.072

Sulfonylurea

    

−0.567

0.891

Thiazolidinedione

    

2.159

0.572

LV ejection fraction

    

0.178

0.602

LV mass index

    

0.348

<0.001

  1. Model 1 means ANCOVA adjusted for baseline E/e′. Model 2 were adjusted for Model 1 and sex, age. Model 3 were adjusted for Model 2 and systolic blood pressure, HbA1c, cardiovascular disease, chronic heart failure, α-glucosidase inhibitor, bigunaide, glinide, sulfonylurea, thiazolidinedione, LV ejection fraction, LV mass index, whose data were obtained at baseline examination
  2. Abbreviations, see Tables 1 and 2
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840